Veeva Systems (VEEV) stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 68 to 72.
↑ XIBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks compares to the rest of the market.
Decades of market research reveals that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating as they begin their largest climbs. See if Veeva Systems stock can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Veeva System stock cleared a cup-with-handle pattern with a 226.47 entry point back in November. Since then, it's pulled back slightly and not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to form a base and break out.
The cloud-based software company for life science industry reported 31% EPS growth in the latest quarterly report, while sales growth came in at 13%.
Veeva Systems stock earns the No. 4 rank among its peers in the Computer Software-Medical industry group. Doximity (DOCS) is the top-ranked stock within the group.
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.